Ask what the evidence actually tested
Ask for the study behind the claim. Was it about people, the same ingredient, the same product form and the same reason for treatment?
Request the result in plain words. Ask what remains unknown and how that uncertainty affects the choice in front of you.
A familiar peptide name may lack approval
The US medicine agency (FDA) had no application record for BPC-157, ipamorelin or retatrutide in the September 26, 2026 check.
FDA application records behind this checkThat means these products have no US approval. Permission to make a medicine from an ingredient is a different legal question. Lack of product approval alone does not settle what a pharmacy may make to order.
Retatrutide has a separate restriction: FDA says it cannot be compounded under federal law. Compounded means made to order as a medicine.
An advisory discussion does not change the rule
As checked on September 26, 2026, a committee advising FDA cannot change the rules by voting. FDA has to complete a formal process before changing which ingredients appear on its list for patient-specific compounding: medicine made for a named patient.
FDA on how the ingredient list changesThat process includes proposing a rule and inviting the public to comment. A committee discussion alone leaves the ingredient rules as they were.